These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 2903342)

  • 41. Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease.
    Chao NJ; Parker PM; Niland JC; Wong RM; Dagis A; Long GD; Nademanee AP; Negrin RS; Snyder DS; Hu WW; Gould KA; Tierney DK; Zwingenberger K; Forman SJ; Blume KG
    Biol Blood Marrow Transplant; 1996 May; 2(2):86-92. PubMed ID: 9118303
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chronic graft-versus-host disease, obliterative bronchiolitis, and graft-versus-leukemia effect: case histories.
    Sullivan KM; Shulman HM
    Transplant Proc; 1989 Jun; 21(3 Suppl 1):51-62. PubMed ID: 2662536
    [No Abstract]   [Full Text] [Related]  

  • 43. FK 506 rescue in chronic graft-versus-host-disease after bone marrow transplantation.
    Tzakis AG; Abu-Elmagd K; Fung JJ; Bloom EJ; Nour B; Greif F; Starzl TE
    Transplant Proc; 1991 Dec; 23(6):3225-7. PubMed ID: 1721416
    [No Abstract]   [Full Text] [Related]  

  • 44. [Thalidomide and graft verses host disease: basis for a new indication and side effects].
    López Gil JA
    Med Clin (Barc); 1992 Oct; 99(14):545-8. PubMed ID: 1434991
    [No Abstract]   [Full Text] [Related]  

  • 45. Life-threatening acute pancreatitis due to thalidomide therapy for chronic graft-versus-host disease.
    Chung LW; Yeh SP; Hsieh CY; Liao YM; Huang HH; Lin CY; Chiu CF
    Ann Hematol; 2008 May; 87(5):421-3. PubMed ID: 18040684
    [No Abstract]   [Full Text] [Related]  

  • 46. [Thalidomide once more in the spotlight].
    de Jong-van den Berg LT; Rutgers J; Cornel MC
    Ned Tijdschr Geneeskd; 1998 Nov; 142(46):2509-12. PubMed ID: 10028338
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation.
    Biagi JJ; Mileshkin L; Grigg AP; Westerman DW; Prince HM
    Bone Marrow Transplant; 2001 Dec; 28(12):1145-50. PubMed ID: 11803357
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Human graft-versus-host disease.
    Parkman R
    Immunodefic Rev; 1991; 2(4):253-64. PubMed ID: 2059433
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Thalidomide for graft-versus-host disease.
    Vogelsang GB; Santos GW; Colvin OM; Chen T
    Lancet; 1988 Apr; 1(8589):827. PubMed ID: 2895345
    [No Abstract]   [Full Text] [Related]  

  • 50. Acute graft-versus-host disease in allogeneic marrow transplantation.
    Parker N; Cohen T
    Nurs Clin North Am; 1983 Sep; 18(3):569-77. PubMed ID: 6351023
    [No Abstract]   [Full Text] [Related]  

  • 51. Phase II study of FK 506 for allogeneic bone marrow transplantation.
    Masaoka T; Shibata H; Kakishita E; Kanamaru A; Takemoto Y; Moriyama Y
    Transplant Proc; 1991 Dec; 23(6):3228-31. PubMed ID: 1721417
    [No Abstract]   [Full Text] [Related]  

  • 52. Low incidence of acute graft versus host disease in Thai patients after allogeneic bone marrow transplantation.
    Jootar S; Intragumtornchai T; Chuncharunee S; Seksan P; Hathirat P
    Transplant Proc; 1994 Aug; 26(4):2354-6. PubMed ID: 8066773
    [No Abstract]   [Full Text] [Related]  

  • 53. Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant.
    Vogelsang GB; Lee L; Bensen-Kennedy DM
    Annu Rev Med; 2003; 54():29-52. PubMed ID: 12359826
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase-1/-2 study of pomalidomide in chronic GvHD.
    Pusic I; Rettig MP; DiPersio JF; Bauer S; McFarland K; Gale RP; Pavletic SZ
    Bone Marrow Transplant; 2016 Apr; 51(4):612-4. PubMed ID: 26657832
    [No Abstract]   [Full Text] [Related]  

  • 55. Factors influencing the risk of acute and chronic graft-versus-host disease in humans: a preliminary report from the IBMTR.
    Bortin MM; Atkinson K; van Bekkum DW; Biggs JC; Dicke KA; Gale RP; Gluckman E; Good RA; Hoffmann RG; Horowitz MM
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():222-4. PubMed ID: 2653507
    [No Abstract]   [Full Text] [Related]  

  • 56. Phases in a drug's use.
    Duffin J
    CMAJ; 1992 Sep; 147(5):588. PubMed ID: 1521204
    [No Abstract]   [Full Text] [Related]  

  • 57. [Acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation].
    Kai S; Shinohara Y; Ifuku H; Ohe Y; Misawa M; Noguchi K; Kohsaki M; Kanamaru A; Hara H; Nagai K
    Rinsho Ketsueki; 1985 Jan; 26(1):20-7. PubMed ID: 3889401
    [No Abstract]   [Full Text] [Related]  

  • 58. [Treatment with thalidomide and production of tumor necrosis factor alpha].
    Pizarro A; Pinilla J; García-Tobaruela A
    Med Clin (Barc); 1993 Jun; 101(4):158. PubMed ID: 8355553
    [No Abstract]   [Full Text] [Related]  

  • 59. [Digestive manifestations of graft-versus-host disease (GVHD) in bone marrow transplantation, organ transplantation and transfusion].
    Li V; Molina L; Michallet M; Hostein J
    Gastroenterol Clin Biol; 1992; 16(1):29-36. PubMed ID: 1537479
    [No Abstract]   [Full Text] [Related]  

  • 60. Orthoclone OKT3 for graft failure after allogeneic bone marrow transplantation: a case report.
    Yen CC; Chen PM; Chiou TJ; Hsieh RK
    Zhonghua Yi Xue Za Zhi (Taipei); 1997 Feb; 59(2):126-31. PubMed ID: 9175303
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.